Hoth Therapeutics Unveils Promising HT-001 Data for Cancer Patients with Skin Toxicities Hoth Therapeutics has announced remarkable results from the HT-001 study, showcasing improved drug exposure and safety for cancer patients suffering skin toxicities.

Hoth Therapeutics Unveils Promising HT-001 Data for Cancer Patients with Skin Toxicities #United_States #New_York #Hoth_Therapeutics #HT-001 #EGFR_Therapy

Kowa's Innovative Antibody-Drug Conjugate Offers New Hope Against EGFR-Expressing Solid Tumors Kowa Company, Ltd. announced significant findings for K-679, a novel antibody-drug conjugate demonstrating superior efficacy in treating solid tumors that express EGFR. The breakthrough highlights advances in cancer therapy.

Kowa's Innovative Antibody-Drug Conjugate Offers New Hope Against EGFR-Expressing Solid Tumors #Japan #Nagoya #K-679 #Kowa_Company #EGFR_Therapy